Format

Send to

Choose Destination
Clin Cancer Res. 2019 Sep 26. pii: clincanres.2213.2018. doi: 10.1158/1078-0432.CCR-18-2213. [Epub ahead of print]

A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.

Author information

1
Molecular and Systems Biology, Geisel School of Medicine at Dartmouth.
2
Quantitative Biomedical Sciences, Department of Molecular & Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth.
3
Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth.
4
Dept. of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth.
5
Pharmacology and Toxicology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth College.
6
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic.
7
Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic.
8
Health Sciences Research, Mayo Clinic.
9
Department of Surgery, Mayo Clinic.
10
EPR Center for Viable Systems, Dartmouth Medical School.
11
Biochemistry and Cell Biology, Dartmouth College.
12
Medicine, Baylor College of Medicine.
13
Oncology, Mayo Clinic.
14
Dept. of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth Todd.W.Miller@Dartmouth.edu.

Abstract

PURPOSE:

We hypothesized that integrated analysis of cancer types from different lineages would reveal novel molecularly defined subgroups with unique therapeutic vulnerabilities. Based on the molecular similarities between subgroups of breast and ovarian cancers, we analyzed these cancers as a single cohort to test our hypothesis.

EXPERIMENTAL DESIGN:

Identification of transcriptional subgroups of cancers and drug sensitivity analyses were performed using mined data. Cell line sensitivity to heat shock protein 90 inhibitors (Hsp90i) was tested in vitro The ability of a transcriptional signature to predict Hsp90i sensitivity was validated using cell lines, and cell line- and patient-derived xenograft models. Mechanisms of Hsp90i sensitivity were uncovered using immunoblot and RNAi.

RESULTS:

Transcriptomic analyses of breast and ovarian cancer cell lines uncovered two mixed subgroups comprised primarily of triple-negative breast and multiple ovarian cancer subtypes. Drug sensitivity analyses revealed that cells of one mixed subgroup are significantly more sensitive to Hsp90i compared to cells from all other cancer lineages evaluated. A gene expression classifier was generated that predicted Hsp90i sensitivity in vitro, and in cell line- and patient-derived xenografts. Cells from the Hsp90i-sensitive subgroup underwent apoptosis mediated by Hsp90i-induced upregulation of the pro-apoptotic proteins Bim and PUMA.

CONCLUSIONS:

Our findings identify Hsp90i as potential therapeutic strategy for a transcriptionally defined subgroup of ovarian and breast cancers. This study demonstrates that gene expression profiles may be useful to identify therapeutic vulnerabilities in tumor types with limited targetable genetic alterations, and to identify molecularly definable cancer subgroups that transcend lineage.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center